Inhaled insulins: the present and future of diabetes therapy

References

• Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:997–86
   Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543–5
   PubMed Web of Science ®Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26 (Suppl 3):S18–24
   PubMed Web of Science ®Google Scholar
• Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239–46
   PubMed Web of Science ®Google Scholar
• Liebl A, Mata M, Eschwege E, for the ODE-2 Advisory Board. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002;45:S23–8
   Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1998 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17–20
   PubMed Web of Science ®Google Scholar
• Comi RJ. Treatment of type 2 diabetes mellitus: a weighty enigma. Ann Intern Med 2005;143:609–10
   PubMed Web of Science ®Google Scholar
• Patton J, Bukar J, Eldon M. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781–801
   PubMed Web of Science ®Google Scholar
• Heineman L, Heise T. Current states of the development of inhaled insulin. Br J Diabetes Vasc Dis 2004;4:295–301
   Google Scholar
• Quattrin T, Bélanger A, Bohannon NJV, et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004;27:2622–7
   PubMed Web of Science ®Google Scholar
• Skyler JS, Weinstock RS, Raskin P, et al., for the Exubera Phase 3 Study Group. Use of inhaled insulin in a basal/bolus regimen in type 1 diabetic subjects. Diabetes Care 2005;28: 1630–5
   Google Scholar
• Norwood P, Dumas R, England RD, et al. Inhaled insulin (Exubera®) achieves tight glycemic control and is well tolerated in patients with type 1 diabetes. Diabetologia 2005;48 (Suppl 1):A30 [abstract 73]
   Google Scholar
• Jovanovic L, Klioze S, Reis J, et al., for the Exubera 1022 Study Group. Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 1 diabetes (T1DM). Diabetes 2006;55 (Suppl 1):A26 [abstract 110-OR]
   Google Scholar
• Garg S, Rosenstock J, Silverman BL, et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006;49:891–9
   PubMed Web of Science ®Google Scholar
• Edgerton DS, Neal DW, Scott M, et al. Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 2005;54:1164–70
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baughman RA, Rivera-Schaub T, et al. A randomized, double-blind, placebo-control study of the efficacy and safety of inhaled Technosphere insulin in patients with type 2 diabetes (T2DM). Diabetes 2005;54\(Suppl 1):A88
   Google Scholar
• Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 2004;27:2356–62
   PubMed Web of Science ®Google Scholar
• Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27:162–7
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Klioze S, Foyt H, et al., for the Exubera 1029 Study Group. Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes 2006;55 (Suppl 1):A26 [abstract 109-OR]
   Google Scholar
• Barnett AH, Dreyer M, Lange P, et al. An open, randomized parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006;29:1282–7
   PubMed Web of Science ®Google Scholar
• Barnett AH, Dreyer M, Lange P, et al. An open, randomized, parallel group study to compare the efficacy and safety profile of inhaled human insulin (Exubera®) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006;29:1818–25
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin (Exubera®) improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized controlled trial. Ann Intern Med 2005;143:549–58
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Bergenstal RM, Cefalu WT, et al., for the Exubera Phase 3 Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 2005;28:1922–8
   Google Scholar
• Hausman M, Dellweg S, Heinemann L, et al. Add-on therapy with Kos inhaled insulin is as efficacious as add-on therapy with Lantus in poorly controlled type 2 diabetic patients treated with sulfonylureas or metformin. Diabetologia 2005;48\(Suppl 1): A297 [abstract 817]
   Google Scholar
• Exubera® [US package insert]. New York, NY. Pfizer Labs, a division of Pfizer Inc; 2006
   Google Scholar
• Wise RA, Ahrens R, Jensen RL, et al. Standardized measurement of single breath diffusing capacity (DLCO) in a multicentre clinical trial. Presented at the American Thoracic Society International Conference, May 20–25, 2005, San Diego, Calif, USA. Proc Am Thorac Soc 2005;2(Suppl) [abstract P2013]
   Google Scholar
• Dreyer M, for the Exubera Phase 3 Study Group. Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type diabetes patients poorly controlled with oral monotherapy. Presented at the 40th Annual Meeting of the European Association for the Study of Diabetes, September 5–9, 2004, Munich, Germany. Diabetologia 2004;47\(Suppl 1):A44
   Google Scholar
• Fineberg SE, Kawabata T, Finco-Kent D, et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial Phase II and III inhaled insulin (Exubera®) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90: 3287–94
   Google Scholar
• Rosenstock J, Cappelleri J, Bolinder B, et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera®) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318–23
   PubMed Web of Science ®Google Scholar
• Hayes RP, Rosenstock J, Muchmore DM, et al. Patient-reported outcomes (PROs) using the Lilly/Alkermes inhaled insulin system versus injectable insulin in patients with type 1 diabetes (T1D). Diabetologia 2005;48\(Suppl 1):A296 [abstract 815]
   Google Scholar
• Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28:427–8
   PubMed Web of Science ®Google Scholar